Skip to Main Content

Advertisement

Umbrella Alt Text
Umbrella Alt Text Close
  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Cancer Research Communications
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics
  • For Authors
    • Information for Authors
    • Author Services
    • Journal Awards
  • About Us
    • AACR Journals
    • Advertising
    • Permissions & Reprints
    • Subscriptions
    • Submit
  • Article Collections
    • Cancer Hallmarks Collection
    • Hot Topics
    • Editors' Picks
    • COVID-19
  • Alerts
  • News
  • Cancer Hallmarks
  • Webinars
Search Dropdown Menu
header search
    Search
    Advanced Search
    User Tools Dropdown
    Register
    Sign In
    Clinical Cancer Research
    Toggle MenuMenu
    • About
      • The Journal
      • Editorial Board
      • AACR Journals
      • Subscriptions
      • Permissions and Reprints
    • Articles
      • Online First
      • Issues
      • Meeting Abstracts
      • Collection: Clinical Trials
      • Collection: Immunotherapy: Facts and Hopes
      • Collection: Editors' Picks
      • COVID-19
    • For Authors
      • Information for Authors
      • Author Services
      • Early Career Award
      • Submit
    • Alerts
    • News
    • Cancer Hallmarks
    • Webinars
    Skip Nav Destination
    Update search
    Querybuilder input 1
    Filter All
    • All
    • Title
    • Author
    • Author Affiliations
    • Full Text
    • Abstract
    • Keyword
    • DOI
    • ISSN
    • EISSN
    • Issue
    • Volume
    • References
    Querybuilder input 2
    Filter All
    • All
    • Title
    • Author
    • Author Affiliations
    • Full Text
    • Abstract
    • Keyword
    • DOI
    • ISSN
    • EISSN
    • Issue
    • Volume
    • References
    Querybuilder input 3
    Filter All
    • All
    • Title
    • Author
    • Author Affiliations
    • Full Text
    • Abstract
    • Keyword
    • DOI
    • ISSN
    • EISSN
    • Issue
    • Volume
    • References
    Querybuilder input 4
    Filter All
    • All
    • Title
    • Author
    • Author Affiliations
    • Full Text
    • Abstract
    • Keyword
    • DOI
    • ISSN
    • EISSN
    • Issue
    • Volume
    • References
    Querybuilder input 5
    Filter All
    • All
    • Title
    • Author
    • Author Affiliations
    • Full Text
    • Abstract
    • Keyword
    • DOI
    • ISSN
    • EISSN
    • Issue
    • Volume
    • References
    Querybuilder input 6
    Filter All
    • All
    • Title
    • Author
    • Author Affiliations
    • Full Text
    • Abstract
    • Keyword
    • DOI
    • ISSN
    • EISSN
    • Issue
    • Volume
    • References

    NARROW

    Format
    Filter by format
    Journal
    Filter by journal
    Article Type
    Filter by article-type
    Issue Section
    Filter by issue-section
    Date
    Filter by date
    Apply
    Availability
    Availability
    1-1 of 1
    Hans Curigliano
    Close
    Save search
    Follow your search
    Access your saved searches in your account
    Would you like to receive an alert when new items match your search?
    Close Modal
    Sort by
    Journal Articles

    Correction: Phase I/Ib Clinical Trial of Sabatolimab, an Anti–TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti–PD-1 Antibody, in Advanced Solid Tumors

    Giuseppe Curigliano, Hans Curigliano, Nicolas Mach, Toshihiko Doi, David Tai, Patrick M. Forde, John Sarantopoulos, Philippe L. Bedard, Chia-Chi Lin, F. Stephen Hodi, Sofie Wilgenhof, Armando Santoro, Catherine A. Sabatos-Peyton, Tyler A. Longmire, Alexandros Xyrafas, Haiying Sun, Sabine Gutzwiller, Luigi Manenti, Aung Naing
    Journal: Clinical Cancer Research
    Clin Cancer Res (2024) 30 (17): 3957.
    https://doi.org/10.1158/1078-0432.CCR-24-2131
    Published: 03 September 2024
    Extract
    View article titled, Correction: Phase I/Ib Clinical Trial of Sabatolimab, an Anti–TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti–PD-1 Antibody, in Advanced Solid Tumors
    Open the PDF for Correction: Phase I/Ib Clinical Trial of Sabatolimab, an Anti–TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti–PD-1 Antibody, in Advanced Solid Tumors in another window

    Advertisement

    Email alerts

    Online First Alert
    eTOC Alert
    Close Modal
    • Issues
    • Online First
    • Collections
    • News
    • Twitter
    • Online ISSN 1557-3265
    • Print ISSN 1078-0432

    AACR Journals

    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Cancer Research Communications
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

     

     

    • Information on Advertising & Reprints
    • Information for Institutions/Librarians
    • RSS Feeds
    • Privacy Policy
    • Twitter
    • LinkedIn
    • Facebook
    • Youtube
    • Copyright © 2023 by the American Association for Cancer Research.
    Close Modal
    Close Modal
    This Feature Is Available To Subscribers Only

    Sign In or Create an Account

    Close Modal
    Close Modal
    This site uses cookies. By continuing to use our website, you are agreeing to our privacy policy.
    Accept